Front Oncol: First-line immunotherapy may improve the prognosis of patients with EGFR-mutant NSCLC after using EGFR-TKI

There are limited data on the use of immune checkpoint inhibitors (ICIs) to treat patients with advanced non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor (EGFR) mutations .
Recently, researchers in many domestic hospitals have carried out related studies to evaluate the efficacy of ICIs in the treatment of advanced NSCLC with EGFR mutations and to explore related influencing factors .
Related results were published in Frontiers in Oncology journal .

There are limited data on the use of immune checkpoint inhibitors (ICIs) to treat patients with advanced non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor (EGFR) mutations .

Recently, researchers in many domestic hospitals have carried out related studies to evaluate the efficacy of ICIs in the treatment of advanced NSCLC with EGFR mutations and to explore related influencing factors .
Related results were published in Frontiers in Oncology journal .
On the use of immune inhibitors checkpoint immunization (ICIS) treatment with epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer ( of NSCLC ) of NSCLC limited patient data

The study collected relevant clinical data of EGFR- mutant NSCLC patients receiving ICIs from many domestic hospitals .

The primary study endpoint is progression-free survival (PFS) , and the secondary study endpoints are overall survival (OS) , objective response rate (ORR) and related influencing factors .

The study collected relevant clinical data of EGFR- mutant NSCLC patients receiving ICIs from many domestic hospitals .
The primary study endpoint is progression-free survival (PFS) , and the secondary study endpoints are overall survival (OS) , objective response rate (ORR) and related influencing factors .
The study collected relevant clinical data of EGFR- mutant NSCLC patients receiving ICIs from many domestic hospitals .
(PFS) , the secondary study endpoints are overall survival (OS) , objective response rate (ORR) and related influencing factors .

Finally, 122 eligible EGFR- mutant NSCLC patients were included
.

The median follow-up time was 15.
4 months ( range : 0.
6-28.
8 months ) , and the median age was 56 years ( range : 30-85 years )

Finally, 122 eligible EGFR- mutant NSCLC patients were included

The ORR of 122 patients was 32.

                     Efficacy evaluation

Efficacy evaluation

              PFS and OS

PFS and OS

All 96 patients with common EGFR- sensitive mutations (19Del and L858R) have previously received EGFR-TKIs treatment
.

All patients who had failed previous TKI treatments and had acquired T790M mutations were treated with osimertinib

All 96 patients with common EGFR- sensitive mutations (19Del and L858R) have previously received EGFR-TKIs treatment

      Comparison of prognosis of first-line and subsequent-line ICI treatment

      Comparison of the prognosis of first-line and subsequent-line ICI treatment

72 patients received based ICI combination therapy : wherein 50 accepts ICI combination chemotherapy, 8 accepts ICI combined chemotherapy and radiotherapy, 12 accepts ICI combined chemotherapy and anti- angiogenesis generation drugs, 2 accepts double ICIS
.

Studies have shown that ICI combination therapy can improve patient prognosis better than ICI monotherapy (mPFS: 5.

72 patients received based ICI combination therapy : wherein 50 accepts ICI combination chemotherapy, 8 accepts ICI combined chemotherapy and radiotherapy, 12 accepts ICI combined chemotherapy and anti- angiogenesis generation drugs, 2 accepts double ICIS

            Comparison of prognosis of ICI combined and single therapy

           Comparison of the prognosis of ICI combined and single treatment.
Comparison of the prognosis of ICI combined and single treatment

Among patients with PD-L1 expression data (n = 69/96, 71.
9%), 31 cases were strongly positive for PD-L1 expression (TPS ≥50%), and 38 cases had PD-L1 expression below 50%
.

Compared with patients with low PD-L1 expression (TPS<50%), patients with strong PD-L1 expression (TPS≥50%) had a significant benefit in PFS (7.

Among patients with PD-L1 expression data (n = 69/96, 71.

               PD-L1 status affects prognosis

               PD-L1 status affects prognosis  PD-L1 status affects prognosis  PD-L1 status affects prognosis             

Multivariate analysis showed that PD-L1 strong positive (TPS ≥50%), ICI-based combination therapy, first-line ICI therapy after EGFR TKI progression, and EGFR L858 mutation patients were all associated with improved PFS (P<0.
05)
.
After adjusting for other clinical factors, good ECOG status, ICI-based combination therapy, and first-line ICI treatment after EGFR TKI progression were found to be independently associated with good OS (P<0.
05)
.

Multivariate analysis showed that PD-L1 strong positive (TPS ≥50%), ICI-based combination therapy, first-line ICI therapy after EGFR TKI progression, and EGFR L858 mutation patients were all associated with improved PFS (P<0.
05)
.
After adjusting for other clinical factors, good ECOG status, ICI-based combination therapy, and first-line ICI treatment after EGFR TKI progression were found to be independently associated with good OS (P<0.
05)
.
Multivariate analysis showed that PD-L1 strong positive (TPS ≥50%), ICI-based combination therapy, first-line ICI therapy after EGFR TKI progression, and EGFR L858 mutation patients were all associated with improved PFS (P<0.
05)
.
After adjusting for other clinical factors, good ECOG status, ICI-based combination therapy, and first-line ICI treatment after EGFR TKI progression were found to be independently associated with good OS (P<0.
05)
.

            Multivariate analysis of prognostic factors

            Multivariate analysis of prognostic related factors Multivariate analysis of prognostic related factors

             The impact of EGFR sensitive mutation subtypes on prognosis

             The impact of              EGFR sensitive mutation subtypes on the prognosis The impact of EGFR sensitive mutation subtypes on the prognosis

In summary, studies have shown that first-line immunotherapy may improve the prognosis of patients with EGFR mutations after using EGFR-TKI
.

In summary, studies have shown that first-line immunotherapy may improve the prognosis of patients with EGFR mutations after using EGFR-TKI
.
Studies have shown that first-line immunotherapy after the use of EGFR-TKI in patients with EGFR mutations may improve the prognosis of patients
.
Studies have shown that first-line immunotherapy after the use of EGFR-TKI in patients with EGFR mutations may improve the prognosis of patients
.

Original source:

Original source:

Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, Lin Z, Chen L, Gong Y, Zhu J, Zhou Q, Huang M and Lu Y (2021) Front-Line ICI-Based Combination Therapy Post -TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Front.
Oncol.
11:739090.
doi: 10.
3389/fonc.
2021.
739090

Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, Lin Z, Chen L, Gong Y, Zhu J, Zhou Q, Huang M and Lu Y (2021) Front-Line ICI-Based Combination Therapy Post -TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Front.
Oncol.
11:739090.
doi: 10.
3389/fonc.
2021.
739090 Leave a message here